Globus Medical, Inc. (GMED) Stock Price & How to Invest

Globus Medical designs and sells musculoskeletal implants and the enabling technology used to place them. The core business is spine: pedicle screws, interbody cages, cervical plates, expandable implants and the disposable instruments that go with them, sold to hospitals and surgery centers largely through a direct sales force. Sitting on top of that is the enabling-technology line, principally the ExcelsiusGPS robotic navigation platform, the Excelsius3D imaging system and the Excelsius Flex robot aimed at knee replacement. The robots themselves are a modest share of revenue; their commercial purpose is to place capital in a hospital and pull recurring implant volume through it for years afterward. The September 2023 all-stock merger with NuVasive roughly doubled the company's size and made it the second largest spine business in the world behind Medtronic, and the April 2025 acquisition of Nevro added spinal cord stimulation for chronic pain, extending Globus beyond surgical implants into neuromodulation.

The investment picture in August 2026 is mostly about integration paying off. Q2 2026 revenue was about $789.6 million, up roughly 6% as reported and around 9% excluding Nevro, with US Spine up about 7% (a fifth straight quarter the company describes as above-market) and international spine up about 14%. The margin story is the sharper one: adjusted EBITDA margin reached roughly 35.4%, an expansion of about 740 basis points year over year, and non-GAAP EPS of about $1.34 grew roughly 56%. Management reaffirmed full-year revenue guidance of about $3.18 billion to $3.22 billion and raised non-GAAP EPS guidance to roughly $4.95 to $5.05 from $4.70 to $4.80. Against that, Nevro sales fell about 14% year over year and management does not expect trial volumes to recover until late in Q4 2026, and a July 2024 FDA warning letter concerning complaint handling and adverse-event reporting for ExcelsiusGPS remains part of the backdrop.

The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. Competition is heavy on both flanks, with Medtronic and its Mazor platform on one side and fast-growing challengers such as Alphatec taking surgeon share on the other, and the surgeon-recruiting lever that drives current outperformance can run in reverse. Regulatory exposure is concrete rather than theoretical: the July 2024 FDA warning letter concerning ExcelsiusGPS complaint handling and medical device reporting is the kind of matter that can escalate to consent decrees or shipment holds if not resolved. Nevro is shrinking, and management's own recovery timeline extends into late 2026, so an impairment is possible if trial volumes stay weak. Plaintiff firms have publicly announced investigations following the 2025 revenue miss and the FDA letter, and product-liability activity around spinal cord stimulators adds separate legal cost that is hard to size in advance.

13 analysts publish price targets on GMED, averaging $103.23 against a $85.90 price as of August 2026, or +20.2%. The published targets run from $84.00 to $125.00, a moderate spread, and the ratings split 10 buy, 5 hold, 0 sell. Over the last six months there have been 4 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GMED forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Globus Medical, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. NuVasive integration and operating leverage. The merger's promised cost synergies are now showing up in reported numbers rather than slides, with adjusted EBITDA margin near 35% and non-GAAP EPS growing several times faster than revenue. The most optimistic published target, $125.00, assumes this works close to its best case.

The case against. The largest structural risk is pricing: spinal implants face steady per-unit price erosion from hospital purchasing groups and payers, so Globus has to grow procedure volume just to hold revenue flat. The most pessimistic target, $84.00, is roughly what GMED is worth if this bites instead.

Read the full bull and bear case on GMED, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Globus Medical, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$3.14 billion
• Q2 2026 revenue: ~$789.6 million, up ~6% year over year (~9% excluding Nevro)
• Q2 2026 EPS: ~$1.10 GAAP, ~$1.34 non-GAAP (non-GAAP up ~56% year over year)
• Adjusted EBITDA margin (Q2 2026): ~35.4%, expanded ~740 basis points year over year
• FY2026 guidance: Revenue ~$3.18 to ~$3.22 billion; non-GAAP EPS raised to ~$4.95 to ~$5.05
• Market capitalization: ~$11.53 billion at ~$85.90 per share

At roughly $85.90 a share against guided non-GAAP EPS of about $5.00, Globus trades near 17 times forward non-GAAP earnings and roughly 3.7 times trailing revenue, a discount to large-cap medtech peers that typically carry higher multiples. The gap reflects the market pricing spine as a low-growth, price-eroding category and discounting the durability of the current margin expansion. Note that the GAAP and non-GAAP figures diverge widely because merger amortization and integration costs are excluded from the adjusted numbers, so the GAAP earnings multiple is considerably higher.

Other names that sit close to GMED: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GMED exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GMED sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GMED fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Globus Medical is a scaled spine-implant business using robotics as a distribution wedge, currently converting the NuVasive integration into real margin expansion, with the open questions being whether above-market spine growth holds and whether the Nevro neuromodulation acquisition stops shrinking.

Whether GMED is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GMED a buy or a sell?, and where the stock could go from here in the GMED stock forecast.

For income investors, whether GMED pays a dividend and how the payout looks is covered in does GMED pay a dividend? And to weigh GMED against a peer, read the full side-by-side comparisons: GMED vs MDT and GMED vs JNJ.